Long-term outcomes of chemoimmunotherapy with obinutuzumab/ chlorambucil in chronic lymphocytic leukemia

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F25%3A10498743" target="_blank" >RIV/00179906:_____/25:10498743 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11150/25:10498743
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=h2BQ14l~C_" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=h2BQ14l~C_</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1182/bloodadvances.2024014875" target="_blank" >10.1182/bloodadvances.2024014875</a>

Result language
angličtina
Original language name
Long-term outcomes of chemoimmunotherapy with obinutuzumab/ chlorambucil in chronic lymphocytic leukemia
Original language description
The article presents the final overall survival data from the randomized phase III trial CLL11 comparing obinutuzumab + chlorambucil vs. rituximab + chlorambucil for the first-line therapy in elderly/comorbid patients, demonstrating survival advantage with obinutuzumab + chlorambucil combination and long remissions in patients with favorable prognostic features.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)